Adult neurogenesis occurs in mammals and provides a mechanism for continuous neural plasticity in the brain. However, little is known about the molecular mechanisms regulating hippocampal neural progenitor cells (NPCs) and whether their fate can be pharmacologically modulated to improve neural plasticity and regeneration. Here, we report the characterization of a small molecule (KHS101) that selectively induces a neuronal differentiation phenotype. Mechanism of action studies revealed a link of KHS101 to cell cycle exit and specific binding to the TACC3 protein, whose knockdown in NPCs recapitulates the KHS101-induced phenotype. Upon systemic administration, KHS101 distributed to the brain and resulted in a significant increase in neuronal differentiation in vivo. Our findings indicate that KHS101 accelerates neuronal differentiation by interaction with TACC3 and may provide a basis for pharmacological intervention directed at endogenous NPCs.
The adult hippocampal dentate gyrus (DG) is a major neurogenic region that harbors self-renewing neural progenitor cells (NPCs). NPCs arise within the subgranular layer (SGL) of the DG and primarily migrate into the adjacent granule cell layer (GCL) to differentiate and mature into neurons (1) . Although adult NPCs hold substantial promise for neural repair after brain injury, their mobilization is hampered 
RESULTS
We previously reported a phenotypic screen that identified a group of synthetic 4-aminothiazole compounds, termed neuropathiazols, which induce neuronal differentiation of cultured rat hippocampal NPCs (9) . Synthesis of several analogs of the original neuropathiazol structure and a focused structure-activity relationship (SAR) study afforded a molecule (KHS101) that possessed increased activity and improved pharmacokinetic properties compared with the original compound (Fig. 1A, Fig. S1 , Scheme S1, Table S1 ). KHS101 was further studied in vitro using established protocols for the isolation, propagation, and differentiation of adult rat hippocampal NPCs (3, (8) (9) (10) . KHS101 increased neuronal differentiation of adherently cultured rat NPCs in a dose-dependent fashion (EC ~ 1 µM) as assessed by quantitative reverse transcription (RT)-PCR for the neurogenic transcription factor NeuroD (11) and immunostaining for the panneuronal marker TuJ1 (Fig. 1 B-D, Fig.  S1 ). KHS101-induced neuron formation (40-60% TuJ1+ cells at 1.5-5 µM KHS101) was also observed under neurosphere-forming conditions (12) in secondary neurospheres derived from both the hippocampus and the subventricular zone (SVZ) of adult rats (Fig. S1 ). Moreover, hippocampal NPCs treated with KHS101 and cultured adherently on microelectrode arrays for 12 d exhibited neuronal morphologies as well as spontaneous spiking activity, hence indicating the presence of functional, maturing neurons (Fig. S2 ).
To further analyze the effect of KHS101 on lineage-specific differentiation, we exposed rat NPCs to the astrocyte-inducing cytokine bone morphogenetic protein 4 (BMP4), which is expressed in the adult neurogenic niches and has been reported to inhibit hippocampal neurogenesis (13) (14) (15) (16) . As expected, BMP4 (50 ng/mL) treatment for 4 d increased differentiation to astrocytes (from 0.5 to 10%) within NPC cultures as assessed by immunostaining for the astrocyte marker glial fibrillary acidic protein (GFAP). Addition of 2 µM RA did not significantly alter BMP4-induced astrogenesis. However, KHS101 (5 µM) treatment decreased BMP4-induced astrocyte differentiation >4-fold, while increasing neuronal differentiation in a dose-dependent fashion (Fig. 1 E-G) . Thus, KHS101 promotes specifically neuronal differentiation and can override the astrocyte-promoting BMP signal.
To elucidate genes and pathways affected by KHS101, we carried out microarray mRNA profiling experiments in adherently cultured rat hippocampal NPCs that were treated with KHS101, the inactive derivative KHS92, or DMSO control. In addition to the expected up-regulation of NeuroD, pathway analysis of differentially regulated genes revealed that KHS101 treatment primarily affects cell cycle regulatory networks in NPCs (Fig. 1H,  Fig. S3 ). Several factors required for cell cycle progression (e.g., cyclins) were down-regulated, whereas microarray mRNA profiling and quantitative RT-PCR experiments showed a marked up-regulation (5- fold at 1.7 µM KHS101) of the negative cell cycle regulator Cdkn1 (Fig. 1 H and I) . This result is consistent with the notion that CDKN1 (also termed p21) plays a key role in regulating the balance between NPC proliferation and differentiation (8, (17) (18) (19) (20) . Analysis of the proliferation marker Ki67, the mitotic marker phospho-histone H3 (P-HH3), and the NPC marker (sex-determining region Y)-box 2 (SOX2), as well as secondary neurosphere formation assays, confirmed that in the presence of KHS101 the vast majority of NPCs stop proliferating within 72 h, become mitotically inactive, and lose Sox2 expression, thus shifting toward terminal differentiation ( Fig. 1 J -L and Figs. S1 and S4). Interestingly, KHS101 decreased the proliferation of rat oligodendrocyte precursor cells from the optic nerve (21) , but failed to induce myelin basic protein expression and oligodendrocyte differentiation in a phenotypic screen, suggesting that KHS101-induced differentiation depends on the cellular context.
To determine the specific target of KHS101 in NPCs, we generated a derivative of the parent compound containing the photocrosslinking benzophenone moiety and an alkyne substituent (KHS101-BP, Fig. 2A and Scheme S5). Upon irradiation this derivative is expected to form a covalent bond between KHS101 and its target protein, allowing isolation of proteincompound complexes after labeling with reporter tags such as biotin-azide. NPC lysate was incubated with KHS101-BP and proteins were separated by 2D SDS/PAGE after UV irradiation and biotin-tag labeling. Western blot analysis identified a distinct labeled protein, whose level was significantly reduced by competition with a 50-fold excess of free KHS101 in independent experiments (Fig. 2B) . Mass spectrometry revealed the 80-kDa protein to be TACC3 and its identity was confirmed by Western blotting using a TACC3-specific antibody (Fig. 2C) . We further confirmed direct physical interaction between TACC3 and KHS101 in independent pulldown experiments using purified recombinant rat TACC3 protein and a biotinylated KHS101 derivative (Fig. 2D , Table S1 ).
TACC3 was originally identified as a member of a protein family with a highly conserved C-terminal coiled-coil domain and is thought to function as an important structural component of the centrosome and mitotic spindle apparatus (22) . Moreover, previous expression studies of Tacc3 as well as loss-offunction studies in mice, hematopoietic stem cells, and embryonic neural stem cells point to a role for Tacc3 in controlling progenitor cell expansion and terminal differentiation during development (23) (24) (25) (26) (27) . Postnatally, TACC3 expression becomes restricted to the remaining proliferative tissues such as spleen, thymus, gastrointestinal (GI) tract, and cerebral areas including the hippocampus (23, 26) .
To address whether Tacc3 is also functionally implicated in the regulation of adult NPC fate, we used RNA interference (RNAi) to specifically down-regulate Tacc3 expression in adult rat hippocampal NPCs. Two different shRNAs (shTacc3-1 and shTacc3-2) efficiently decreased Tacc3 RNA levels (60-90% reduction in independent experiments) compared with the nontargeting control shRNA (shCO) as assessed by quantitative RT-PCR and immunocytochemistry ( Fig. 3 A-C, Fig. S4 ). Cdkn1 RNA levels markedly increased (~4-fold, Fig. 3A ) upon treatment with Tacc3-specific shRNAs, which is consistent with KHS101-induced up-regulation of Cdkn1 and with previous reports showing that TACC3 depletion causes CDKN1-mediated cell cycle inhibition in fibroblasts (28) . Furthermore, an overt neuronal differentiation phenotype and a concomitant reduction in NPC marker immunoreactivity (Nestin, Sox2) were observed in NPC cultures ~4 d after treatment with Tacc3-specific shRNAs ( Fig. 3 B-F) ; staining for TuJ1 and Ki67 confirmed a significant increase in TuJ1+ neurons (~4-fold) and decrease in proliferation (≥3-fold) compared with shCO-expressing NPCs (Fig. 3G ). In addition, Tacc3-specific shRNAs significantly suppressed GFAP+ astrocyte formation and concomitantly promoted neuronal differentiation of NPCs http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944756/ KHS101 Regulates the Nuclear Localization of the Transcription Factor ARNT2.
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cultured in the presence of BMP4 (Fig. 3 H-J) . Thus, TACC3 is required for the maintenance of the undifferentiated NPC state in vitro and its knockdown is sufficient to fully recapitulate the neurogenesis and astrocyte-suppressing phenotypes induced by KHS101. Although the contribution of other KHS101 binding partners cannot be excluded, TACC3 appears to be the functionally relevant target of KHS101 in NPCs.
Recently, TACC3 was proposed to regulate cell fate decisions by controlling the subcellular localization of transcription factors, including aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2) (24, 26) . Interestingly, ARNT2 is the only known TACC3-interacting protein that is almost exclusively expressed in neuronal brain cells throughout life (29) ; consistent with this report ARNT2 expression was detected within the DG by immunohistochemistry (Fig. S4) . Moreover, the expression of several genes downstream of ARNT2-mediated signaling was affected by KHS101 in cultured NPCs, including genes involved in arylhydrocarbon receptor signaling (Fig. S3) . To further investigate the putative neurogenic mechanisms downstream of the TACC3-KHS101 interaction, we analyzed nuclear localization of ARNT2. Consistent with a previous report (30) , transient overexpression of rat TACC3 diminished nuclear localization of ectopically expressed rat ARNT2 in a concentration-dependent manner in 293T cells (Fig. 3K) . In contrast, KHS101 treatment led to increased nuclear but not cytoplasmic levels of ARNT2 (Fig. 3L) . Furthermore, treatment with KHS101 (5 µM, 12 h) or Tacc3-specific shRNAs increased the levels of endogenous nuclear ARNT2 in NPCs as quantified by confocal microscopy and image analysis ( Fig. 3 M and N, and Fig. S4 ). Next, we tested whether ARNT2 can regulate cell fate in adult hippocampal NPCs by transient Arnt2 overexpression. Elevated levels of ARNT2 were detected in the nuclei of NPCs but were insufficient to induce cell cycle exit or NPC differentiation. However, ARNT2 overexpression markedly favored neurogenesis and suppressed the astrocyte cell fate upon BMP4-induced differentiation (Fig. S5) , suggesting that ARNT2 may provide a cell-intrinsic bias toward neuronal lineage specification of NPCs in response to glial-inducing signals.
To determine whether KHS101 can act as a pharmacological agent to induce neuronal differentiation in vivo, we assessed the pharmacokinetic properties of KHS101 including blood-brain barrier penetration. Oral administration in vehicle resulted in very low systemic exposures; however, i.v. and s.c. doses of 6 mg/kg KHS101 resulted in reasonable plasma concentrations (>1.5 µM) with a plasma half-life of 1.1-1.4 h, and a relative bioavailability of 69% following s.c. dosing. Most importantly, the distribution of KHS101 to the brain was extensive as demonstrated by a brain-to-plasma AUC ratio of ~8 (dosing: 3 mg/kg KHS101, i.v.; Fig. 4A , Table  S2 ). Consequently, to study the effect of KHS101 on neurogenesis we injected adult rats with vehicle (5% EtOH in 15% Captisol) or KHS101 (s.c., 6 mg/kg, BID) for 14 d, while including a daily bromodeoxyuridine (BrdU) regimen (200 mg/kg, intraperitoneal) for the first 7 d to label dividing NPCs in the DG. We then examined the fate of those BrdU-labeled cells by assessing colocalization with the astrocyte marker GFAP and the neuronal-specific nuclear protein NeuN (Fig. 4 B and C, Fig. S6 ).
No significant difference was detected in the percentage of BrdU/GFAP double-positive cells upon KHS101 treatment. However, the majority of these cells (>80%) were nonstellate and located within the SGL, therefore likely representing a NPC subtype (GFAP+ type I progenitors) (1), rather than differentiated astrocytes (Fig. S6) . Notably, we found a significant increase in the percentage of BrdU/NeuN double-positive cells from ~20 to ~40% upon KHS101 dosing, indicating increased neuronal differentiation. Consistent with this result, the number of Ki67-and BrdU-positive cells significantly (0-3h) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944756/ decreased within the SGL, indicating reduced proliferation of NPCs in KHS101 compared with vehicletreated animals (Fig. 4 D-F and H) . The remaining Ki67 and BrdU immunoreactivity within the SGL of treated animals suggests that the KHS101 dosing regimen did not result in the exhaustion of the selfrenewing progenitor pool. Moreover, KHS101 administration did not alter Ki67 immunostaining in nonneural TACC3-expressing tissues such as spleen and gut (Fig. S7) , suggesting either a cell typespecific effect of KHS101 or different levels of exposure or clearance in different organs. Finally, we did not observe signs of lethargy, weight loss, or other indicators of sickness in KHS101-treated animals during the study period and apoptosis was not altered within the DG of KHS101-compared with vehicleinjected animals as assessed by cleaved caspase 3 staining. Overall, these results are consistent with our in vitro data and indicate a significant KHS101-induced acceleration of neuronal differentiation in vivo.
DISCUSSION
Endogenous pools of NPCs are a potential source for tissue repair and regeneration in the central nervous system (CNS). NPCs are able to self-renew throughout life in a location-specific manner and their fate may be modulated in response to pharmacological intervention with small molecules. NPC-mediated neurogenesis involves at least three different processes: NPC proliferation, differentiation, and the survival of NPCs committed toward a neuronal fate. Small molecules have been shown to modulate each of these distinct processes. For example, the antidepressant agent fluoxetin has been shown to increase NPC proliferation in vivo (5) , and the anticonvulsant drug valproate has been shown to increase neuronal differentiation of NPCs in the adult rat dentate gyrus (3). A very recent study describes the identification of a proneurogenic small molecule that protects newborn hippocampal neurons from apoptosis (31) . Moreover, a series of experimental small molecules that control the self-renewal and differentiation of stem and progenitor cells in vitro have been described (3, 9, (32) (33) (34) (35) (36) .
This study shows that small molecules such as KHS101, isolated from phenotypic screens of chemical libraries, can be powerful tools to elucidate and modulate the biology of endogenous progenitor cells both in vitro and in vivo. KHS101 specifically promoted neuronal differentiation of NPCs, concomitantly suppressing proliferation. The levels of KHS101-induced NPC differentiation were qualitatively comparable to those induced by the known neurogenic factors RA and BDNF under adherent and sphereforming conditions (Fig. S1 ), although the optimal concentrations varied (2-5 µM for KHS101, 2 µM for RA). However, unlike most known neurogenic factors, KHS101 can override astrocyte-inducing cues such as BMP4 in favor of neuronal differentiation. Affinity-based purification methodology revealed physical interaction of KHS101 with TACC3, although binding of KHS101 to other cellular proteins cannot be excluded. Importantly, knockdown of TACC3 caused a strong neuronal differentiation phenotype and also blocked BMP-induced astrocyte formation in cultured NPCs in a comparable fashion to KHS101 treatment, suggesting that TACC3 is likely the most relevant biological target of KHS101. Interestingly, KHS101 treatment and knockdown of TACC3 led to increased nuclear localization of the nervous systemspecific transcription factor ARNT2, and overexpression of ARNT2 markedly favored neuronal differentiation over the astrocyte cell fate upon BMP-induced differentiation.
Taken together, these findings indicate that KHS101 specifically accelerates neuronal differentiation by interaction with the TACC3 protein and support a functional link between KHS101 and the TACC3-ARNT2 axis. Our findings suggest that shRNA-or KHS101-mediated interference with TACC3 accelerates neurogenesis through negative regulation of the cell cycle and concomitant activation of a neuronal differentiation program in NPCs. A body of literature suggests that TACC3 is playing a crucial role in progenitor cell maintenance and is down-regulated upon differentiation (23) (24) (25) (26) (27) 37) , although the http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944756/ Hippocampal NPC Culture.
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molecular mechanisms downstream of TACC3 have yet to be determined. As proposed in a previous study (24) , TACC3 may sequester distinct transcription factors to the cytoplasm or to the centrosome, therefore preventing them from binding to transcriptionally active promoters. Alternatively, TACC3 may modulate the proteolytic turnover of its binding partners by providing a target for proteasomal degradation. Overall, it is conceivable that the regulation of TACC3 and its downstream interaction partners strongly depends on the cellular context (e.g., tissue type and state of the cell cycle) and that specific TACC3 binding transcription factors, such as ARNT2, may actively contribute to lineage-specific progenitor cell differentiation as a result of TACC3 modulation.
It is a common notion that NPC proliferation increases after injury to the CNS (38) . Thus, differentiationinducing agents such as KHS101 may lead to new therapeutics that act by enhancing the contribution of newborn cells to CNS repair. Moreover, KHS101 may affect the self-renewal potential of malignant progenitor-like cells that can fuel aggressive brain cancer such as glioblastoma multiforme and have been shown to share several functional features as well as in vitro growth conditions with normal neural progenitor cells (39) (40) (41) . Future research will shed light on the molecular nature of the KHS101-TACC3 interaction, the cell type-and age-specific roles of TACC3, and a potential therapeutic effect of KHS101 in animal models of neurodegeneration and CNS malignancies.
METHODS
Rat NPCs were derived and cultured as described previously by others (10) . After hippocampal cell isolation, the number of dissociated cells was determined and ~5 × 10 cells were plated in 60-mm uncoated plates. After overnight incubation (37 °C, 5% CO , and 95% humidity), the medium was changed and the cells were expanded and maintained in an undifferentiated state on polyornithine-(10 µg/mL in water; Sigma) and laminin-coated (5 µg/mL in PBS; Invitrogen) dishes in DMEM/F12 (Invitrogen) supplemented with N2 (Invitrogen) and basic fibroblast growth factor (bFGF, 20 ng/mL; Invitrogen). For KHS101 and shRNA-induction experiments, early passage cells (passaged no more than six times after hippocampal isolation) were trypsinized and plated at a density of ~1,000 cells/cm into N2 medium (DMEM/F12 supplemented with N2) containing KHS analogs (e.g., KHS101, KHS92, and NP; SI Text) at different concentrations (0.5-5 µM) or DMSO (0.1%), RA (1-2 µM), BDNF (100 ng/mL), and/or BMP4 (50-100 ng/mL) for 4 d.
Total RNA was purified using the RNeasy kit (Qiagen) and cDNA was produced using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). TaqMan probes for rat NeuroD, Tacc3, and Gapdh gene expression assays were purchased from Applied Biosystems and used according to the manufacturer's instructions.
Cells were fixed with 10% (vol/vol) formalin solution at room temperature (RT) for 10 min, permeabilized with 0.5% (vol/vol) Triton X-100 (Sigma) in PBS for 10 min, and then blocked with PBS containing 0.3% (vol/vol) Triton X-100, 10% FCS, 1% (wt/vol) BSA at RT for 1 h. Cells were incubated with primary antibodies (SI Text) in a PBS solution containing 0.1% (vol/vol) Triton X-100 and 5% FCS at 4 °C overnight.
NPC lysate was prepared by sonication in PBS and protein samples were prepared at a concentration of 2 mg/mL. The benzophenone-KHS101 compound (KHS101-BP, 5 µM; SI Text) was added to 50 µL of the proteome reaction with and without unlabeled compound (250 µM). Irradiation was for 1 h using a hand-held UV lamp at long wavelength (365 nm), and subsequently a copper-catalyzed azide-alkyne cycloaddition reaction was performed (SI Text). After incubation for 1 h at RT, proteins were precipitated using trichloroacetic acid and resuspended in isoelectric focusing sample buffer. 2D SDS/PAGE was performed using ReadyStripe IPG stripes (Bio-Rad) following the manufacturer's protocol.
Electroporation of plasmid DNA (SI Text) into hippocampal NPCs was performed using the rat neural stem cell Nucleofector Kit (Lonza) according to the manufacturer's protocol. All shRNA and cDNA expression vectors harbored a puromycin resistance gene allowing for the selection of cells expressing plasmid DNA.
To investigate the pharmacokinetic properties of KHS101, male Sprague-Dawley rats were administered 3 mg/kg KHS101 i.v. or s.c. One rat was killed per time point at 5 min, 40 min, 1 h, and 3 h after dosing, and samples of blood (100 µL) and whole brains were collected. In a separate study, rats were administered 6 mg/kg KHS101 i.v. or s.c. Five blood samples of 100 µL each were collected serially via a jugular vein catheter at 2 min (i.v. only), 0.5 h (s.c. only), and 1, 3, 7 and 24 h after dosing. Plasma and homogenized whole brain samples were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). To study neuronal differentiation upon KHS101 administration in vivo, adult Fisher 344 rats (~10 wk old) received s.c. injections of 6 mg/kg KHS101 or vehicle control (5% ethanol in 15% Captisol). All rats received one daily i.p. injection of 200 mg/kg BrdU for 6 consecutive days after the first day. After 14 d, the animals were killed and perfusion fixed, and the brains were removed and subjected to immunohistochemical analysis (SI Text).
Detailed experimental procedures can be found in SI Text. (Fig. S4) . (Scale bars: 20 µm.) Error bars, SDs (three independent experiments; biological replicates in A); statistical significance (t test), *P < 0.05, **P < 0.01; nuclei were visualized with DAPI (blue). 
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